![](https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1168877430%20%282%29_0.jpg?VersionId=zBX6FhIeONipG7BHDFvMto8s4yapEBRc)
AstraZeneca's Calquence and Amgen's Lumakras clinch FDA label expansions
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA approvals. Calquence, in combination with chemotherapy bendamustine and Roche’s Rituxan, can now treat patients with previously untreated …